news
MHRA approves Leqembi IV maintenance as additional Alzheimer’s option
Decision provides UK Alzheimer’s patients with an alternative administration method for Eisai and Biogen’s antibody drug.
List view / Grid view
Drug Development
news
Lilly bolsters leadership team with neuroscience and immunology in mind
Dr Carole Ho joins from Denali Therapeutics and there are promotions for Adrienne Brown and Daniel Skovronsky.
news
MHRA set to overhaul the UK’s rare disease drug regulatory pathway
The medicines regulator will aim to take a more flexible licensing approach for the research and manufacture of rare disease therapies in the UK.
news
Pfizer and Novo Nordisk battle for obesity market dominance
Novo Nordisk’s “bold” $6.5 billion bid subject to a final verdict by Metsera’s board of directors.
news
FDA draft guidance on biosimilars offers “regulatory relief”
US agency follows in footsteps of European Medicines Agency (EMA) in efforts to streamline biosimilar development.
news
Lilly AI factory to accelerate pharmaceutical manufacturing and development
Pharma giant plans to harness its “decades of data” and use AI to set a new scientific standard that accelerates pharmaceutical innovation.
news
Taiwan talks evidence-driven TCM at CPHI Frankfurt
Scientific and commercial opportunity for pharma companies looking to source, co develop and manufacture traditional Chinese medicine (TCM).
news
AI/ML investment strong as UK biotech weathers economic strain
With Q3 2025 venture capital figures representing “a fragile moment” for the UK biotech sector, BIA says sustained government action is needed to secure its global competitive edge.
news
Novartis strengthens neuroscience pipeline with $12bn Avidity acquisition
Deal to advance potential first-in-class RNA therapeutics focused on genetic neuromuscular diseases such as Duchenne muscular dystrophy.
news
Lilly’s baricitinib exhibits paediatric potential in major alopecia areata study
Results from the phase III study signify a successful collaboration with biopharma firm Incyte.
news
Ipsen strikes €1bn deal to acquire French biotech ImCheck Therapeutics
The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.
news
Keytruda post-surgery could halt return of distant tumours in rare skin cancer
Merck & Co’s anti-PD-1 immunotherapy showed evidence at ESMO of its ability to prevent cancer recurrence in Merkel cell carcinoma.
news
Europe unveils science strategy as it looks to become an ‘AI continent’
Establishes Resource for AI Science in Europe and eyes frontier AI models and autonomous agentic AI for pharma.
![Close up view of the Merck logo on the top corner of a glass building [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-aquisition-300x278.jpg)
![Close up view of the Merck logo on the top corner of a glass building [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-aquisition-scaled-e1605009301887.jpg)
news
Merck & Co starts phase IIb study of tulisokibart in rheumatoid arthritis
The study is one of three to start, along with those in hidradenitis suppurativa and radiographic axial spondyloarthritis.
webinar
Automating quality control testing for radiopharmaceutical production
7 October 2025 | By Rapid Micro Biosystems
This webinar showcases a rapid microbial method that can help to address the time to result challenge posed by short shelf-life radiopharmaceuticals.
